InnoCan Pharma (FRA:IP40) Tax Provision: €-0.20 Mil (TTM As of Mar. 2026)


FRA:IP40 InnoCan Pharma Corp FRA:IP40
54 GF Score
Price €1.92
GF Value €9.36
Valuation Possible Value Trap
! 2 Warning Signs
View Full Analysis

What is InnoCan Pharma Tax Provision?

InnoCan Pharma FRA:IP40 -1.54% 54 Tax Provision is €-0.20 Mil as of Mar. 2026. GuruFocus rates FRA:IP40 with a GF Score™ of 54/100 and a GF Value™ of €9.36 (Possible Value Trap). The stock has 2 warning signs investors should review.

InnoCan Pharma's tax provision for the three months ended in Mar. 2026 was €-0.06 Mil. Its tax provision for the trailing twelve months (TTM) ended in Mar. 2026 was €-0.20 Mil.

InnoCan Pharma Tax Provision Historical Data

* Premium members only.

The historical data trend for InnoCan Pharma's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

InnoCan Pharma Tax Provision Chart

InnoCan Pharma Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Tax Provision
Get a 7-Day Free Trial 0.00 -0.00 -0.20 -1.13 -0.36

InnoCan Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Tax Provision Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.24 -0.18 -0.19 0.22 -0.06
FRA:IP40
54GF Score
InnoCan Pharma Corp FRA:IP40
Tax Provision is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

InnoCan Pharma Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.20 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Tax Provision →
What does a Tax Provision of €-0.20 Mil mean?
InnoCan Pharma (FRA:IP40) has a Tax Provision of €-0.20 Mil as of Mar. 2026. Provision for taxes is the amount of tax the company owes based on pre-tax income. View historical data on InnoCan Pharma and its competitors.
Is InnoCan Pharma's Tax Provision too high?
InnoCan Pharma's current Tax Provision is €-0.20 Mil. Overall, InnoCan Pharma has a GF Score™ of 54/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does InnoCan Pharma's Tax Provision compare to PG and CL?
InnoCan Pharma's Tax Provision of €-0.20 Mil can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tax Provision for a Consumer Packaged Goods company?
A good Tax Provision depends on the Consumer Packaged Goods industry context. However, Tax Provision should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tax Provision mean?
A high Tax Provision can signal that a stock is expensive relative to its fundamentals. Provision for taxes is the amount of tax the company owes based on pre-tax income. View historical data on InnoCan Pharma and its competitors. InnoCan Pharma's current Tax Provision is €-0.20 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InnoCan Pharma stock overvalued right now?
Based on GuruFocus' analysis, InnoCan Pharma (FRA:IP40) is currently considered Possible Value Trap. The stock's GF Value™ is €9.36, compared to a current price of €1.92 — trading 79.5% below its estimated fair value. The current Tax Provision is €-0.20 Mil. InnoCan Pharma's overall GF Score™ is 54/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tax Provision calculated?
Tax Provision is calculated from a company's financial statements. For InnoCan Pharma (FRA:IP40), the current Tax Provision is €-0.20 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is InnoCan Pharma (FRA:IP40) Overvalued in 2026?

Based on GuruFocus' analysis, InnoCan Pharma stock appears to be undervalued. The current stock price of €1.92 is trading 79.5% below its estimated GF Value™ of €9.36. GuruFocus considers InnoCan Pharma to be Possible Value Trap.

Key valuation signals for FRA:IP40:

  • Tax Provision: €-0.20 Mil
  • GF Value™: €9.36 vs. price of €1.92 (79.5% below fair value)
  • GF Score™: 54/100 with 2 warning signs

No single metric tells the full story. See the FRA:IP40 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

InnoCan Pharma Business Description

Address 1015, 926 - 5 Avenue SW, Calgary, AB, CAN, T2P 0N7
InnoCan Pharma Corp develops consumer wellness and pharmaceutical products. It has developed a preclinical-stage Cannabidiol-loaded Liposome injection Platform (CBD-LPT) for non-opioid pain management, and is involved in developing and marketing various self-care and CBD beauty products. Additionally, the Group offers cosmetic products such as anti-aging beauty sleeping masks, anti-puffiness eye serum, anti-aging facial serum, hair cream, etc., which are sold mainly through online marketplaces. Its operating segments are: Online sales and Other operations. The majority of its revenue is generated from the Online sales segment, which engages in the development, manufacture, and marketing of cosmetic products. Geographically, the Group generates maximum revenue from the United States.
54GF Score

Get the complete analysis for FRA:IP40

Tax Provision is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.92
Price
€9.36
GF Value